PDS Biotechnology Corp (PDSB)

[Fress]

Beautiful reset.


Company is about to drop some massive hammers on the bears.

NVAX:1 year 3.54 Low 144 High +2,914% 52 week gain.8 billion MC

MRNA 1 year 11.00 Low 95.00 High +570% 52 week gain 36 billion MC

INO 1 year 1.92 Low 33.79. High 33.79 +877% 52 week gain 4 billion MC

VXRT 1 year .72 Low 17.49 High. +2,087% 52 week gain. 2 billion MC

PDSB.1 year .61 Low 6.71 High -31.06% 52 week loss 56 million MC
VERSAMUNE® PLATFORM Infectious disease & cancer T cells vaccine platform.

clinical testing of PDS Biotech’s Versamune®-based COVID-19
vaccine candidates is ongoing with a clear target profile:

PDSB Covid-19 Vaccine's:
1.Induction of highly-potent, SARS-CoV-2-specific killer 1 T-cells.

2.Demonstrate high levels of both SARS-CoV-2-specific 2 T-cell and antibody response after a single dose.

3 No safety signals.

4 Poised for rapid commercial scale up.

this can run 200-300%+ in a blink of an eye with a 60 million market cap valuation. Covid-19 Vaccine Robust long lasting
T cell Platform

July 2020 PDSB company presentation:
https://www.pdsbiotech.com/images/presentation/PDS_Biotech_Corporate_Presentation-JULY2020.pdf

www.pdsbiotech.com


$PDSB